RxDoctor Payments Data

Susan Hooten, APRN

Gerontology · Morrilton, ARNPI 1629422266

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 27.1% of the total. That places this record below the midpoint for gerontology clinicians in AR, where the typical reported total is $336.

$357in general payments, 2019–2025

Across 17 payments — averaging $21.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$97
  • GSK$69
  • Otsuka America Pharmaceutical, Inc.$64
  • AstraZeneca$49
  • Lilly USA, LLC$46
  • Axsome Therapeutics, Inc.$19
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$357100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$357 in reported general payments places this provider in the 50th percentile of 89 gerontology providers in Arkansas.

See all gerontology providers in Arkansas

Medicare billing

Part B allowed, 2024
$27,146
Medicare patients
245
Services billed
332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe81$66,101
OzempicSemaglutide35$42,256
MounjaroTirzepatide30$41,077
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$37,379
JardianceEmpagliflozin30$36,964
QuliptaAtogepant33$34,959
UbrelvyUbrogepant20$25,327
FarxigaDapagliflozin Propanediol24$23,353
TrulicityDulaglutide22$22,108
RexultiBrexpiprazole13$20,892
XareltoRivaroxaban24$19,735
Oxtellar XrOxcarbazepine13$19,186
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$19,180
EliquisApixaban19$16,150
NeuproRotigotine11$16,066

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$46$63,18552 claims
AbbVieQulipta, Ubrelvy$97$60,28653 claims
AstraZenecaFarxiga, Breztri Aerosphere$49$42,53342 claims
GSKTrelegy Ellipta$69$37,37948 claims
Otsuka America Pharmaceutical, Inc.Rexulti$64$20,89213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 89 gerontology providers in Arkansas.

Other gerontology in Morrilton

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →